Galapagos NV dropped its Q1 2026 results after market close on May 6, delivering a split verdict that keeps the debate around this Belgian biotech very much alive.
The headline read was mixed. Q1 EPS came in at $0.25, well ahead of the consensus estimate of -$1.27 — a beat that ranks Galapagos in the 91st percentile for EPS surprise across the broader universe. Revenue, at $6.5–$7.6 million, missed the $16 million estimate by a wide margin. The earnings call follows on May 7, where management's business update will draw more scrutiny than the numbers themselves. Full-year 2025 results, reported in February, showed a dramatic turnaround — revenue of EUR 1.11 billion versus EUR 276 million a year prior, with net income swinging to EUR 321 million.
The borrow market carries no alarm signals ahead of or after this print. Short interest is a modest 0.77% of free float, little changed on the week and down from around 0.98% in mid-March. Availability is extremely loose at around 900% of short interest — meaning there is roughly nine times more stock available to borrow than is currently borrowed. Cost to borrow ticked up 7% on the week to 2.54%, and is about 15% higher than a month ago, but remains a low absolute rate. The ORTEX short score of 38 — and its gradual creep higher from 36.3 on April 22 — reflects slow-building rather than aggressive short pressure.
The factor picture underscores the contradictions in this name. The 90-day EPS momentum rank of 98 is exceptional, and the EPS surprise rank at 91 confirms consistent beat history. Yet 12-month forward EPS growth ranks near the bottom at just 11 — the Street does not yet believe the acceleration is durable. Price/book of 0.54 flags the stock as trading well below its book value. EV/EBITDA near 7.5 has nudged higher over the past month. With analyst data last updated in August 2022, no current consensus target can be reliably cited here.
The ownership structure adds a layer of stability, and some complexity. Gilead Sciences holds 25.4% of the company — an anchor stake that has not moved recently. Tang Capital, the second-largest institutional holder at 7.9%, trimmed by 648,000 shares as of year-end 2025. EcoR1, which holds a board seat, has been an active buyer: the fund bought over 228,000 shares in May and June 2025 at prices between €23 and €25, a range the stock is currently trading within. That insider-adjacent accumulation at current levels is a relevant data point heading into Wednesday's call.
Correlated peers were mostly lower on the week. VIR fell nearly 6%, CRBU dropped 9.4%, and ONCY lost 5.5%. The exception was UNCY, which gained 11.8%. GMAB — perhaps the closest European biotech comparable — rose modestly, up 1.7% on the week. Galapagos itself was nearly flat, up 0.3% over five sessions, suggesting it held up relatively well in a weak tape for the peer group.
The May 7 earnings call is the next key moment — the revenue miss and the mismatch between short-term earnings beats and subdued long-term EPS growth forecasts are exactly the tensions management will need to address.
See the live data behind this article on ORTEX.
Open GLPG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
